探討晚期非小細胞肺癌接受標靶治療不同階段的患者皮膚毒性嚴重度差異

Comparison of Severity of Skin Toxicity in Different Stages of Patients with Advanced Non-small Cell lung Cancer Receiving Targeted Therap

10.6386/CGN.202003_31(1).0002

曾麗娟(Li-Chuan Tseng)；翁麗雀(Li-Chueh Weng)；王智亮(Chih-Liang Wang)；陳綱華(Kang-Hua Chen)

非小細胞肺癌 ； 標靶治療 ； 皮膚毒性 ； 甲溝炎 ； non-small cell lung cancer ； targeted therapy ； skin toxicity ； paronychia

長庚護理

31卷1期（2020 / 03 / 01）

12 - 25

繁體中文

晚期非小細胞肺癌患者需要接受表皮生長因子接受器－酪胺酸激酶抑制劑類的標靶藥物治療，治療期間90－100%的患者會出現皮膚毒性。標靶治療引起之皮膚毒性在服藥1週左右就會出現，有些症狀是持續服藥半年後陸續發生。皮膚毒性反應無法避免但可控制，為了在適當時機對患者提出合宜之衛教，本文研究目的是要瞭解非小細胞肺癌患者接受標靶治療1個月內及1個月以上常見之皮膚毒性種類，並比較嚴重度之差異。本研究為探索性研究，採橫斷式研究設計，收案場所為北部某醫學中心之胸腔內科、腫瘤科門診及病房，以方便取樣選取符合收案條件之患者。自2015年7月至2016年3月有效樣本共149位，無論接受標靶治療1個月內或1個月以上，患者過半皆出現皮膚乾燥、皮膚搔癢、丘疹膿疱、口腔黏膜炎等皮膚毒性症狀，而甲溝炎則是在治療1至3個月期間過半人數出現。接受標靶治療1個月內及1個月以上的患者，出現甲溝炎人數有顯著差異（χ^2=4.478，p＜.05）。接受標靶藥物治療初期，醫療人員需提供患者全面性的皮膚與口腔照護衛生教育，服藥1個月之後，更需加強指（趾）甲照護。在適當時機對患者與其家屬強調照護重點，不僅可以強化衛教成效，更能提升患者皮膚照護自我管理能力與生活品質。

Patients with advanced non-small cell lung cancer need long-term treatment for targeted therapy. About 90-100% of the patients receiving EGFR-tyrosine kinase inhibitor will experience skin toxicities after one week of targeted therapy. Patients also experience other side effects sequentially half a year after treatment. These skin reactions are inevitable but controllable. Therefore, providing effective education in appropriate time is critical. The purpose of this study was to explore several common skin toxicities among patients receiving targeted therapy for less than and more than one month and compare the difference in severity. This study is an exploratory and cross-sectional design. Convenient sampling was used to recruit patients from thoracic and oncology ward and outpatient department of a medical center in northern Taiwan. One hundred and forty-nine patients were included in this study from July 2015 to March 2016. Results showed that more than 50% patients both receiving targeted therapy for less than and more than one month have experiences of dry skin, pruritus, rash acneiform, and/or oral mucositis. Half of the patients experienced paronychia within 1 to 3 months after treatment. There is a significant difference in the incidence of paronychia between patients receiving treatment for less than and more than one month (χ^2 =4.478, p＜ .05). Health care provider need to provide a comprehensive education of skin and oral care to the patients in the initial stage of targeted therapy. Finger and toe care are especially emphasized one month after treatment. By emphasizing timely care to patients and their family members, this study promotes the value of education and patient's skin care ability and quality of life.

1. 張黎露, L. L.,朱家瑜, C. Y.,姜紹青, S. C.,許麗珠, L. C.,黃國埕, K. C.,周文珊, W. S.,侯秀香, H. H.(2015)。標靶治療藥品之皮膚毒性預防及照護指引。腫瘤護理雜誌，15，47-80。
   連結：
2. Agero, A. L.,Dusza, S. W.,Benvenuto-Andrade, C.,Busam, K. J.,Myskowski, P.,Halpern, A. C.(2006).Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.Journal of the American Academy of Dermatology,55(4),657-670.
3. American Joint Committee on Cancer (2018). Cancer staging system. Retrieved from https://cancerstaging.org/references-tools/Pages/What-is-Cancer-Staging.aspx
4. Boone, S. L.,Rademaker, A.,Liu, D.,Pfeiffer, C.,Mauro, D. J.,Lacouture, M. E.(2007).Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: Survey results.Current Oncology,16(1),16-26.
5. Buccheri, G.,Ferrigno, D.,Tamburini, M.(1996).Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution.European Journal of Cancer,32(7),1135-1141.
6. Chow, R.,Chiu, N.,Bruera, E.,Krishnan, M.,Chiu, L.,Lam,Chow, E.(2016).Inter-rater reliability in performance status assessment among health care professionals: A systematic review.Annals of Palliative Medicine,5(2),83-92.
7. Conill, C.,Verger, E.,Salamero, M.(1990).Performance status assessment in cancer patients.Cancer,65(8),1864-1866.
8. Dueck, A. C.,Mendoza, T. R.,Mitchell, S. A.,Reeve, B. B.,Castro, K. M.,Rogak, L.,National Cancer Institute PRO-CTCAE Study Group(2016).Validity and reliability of the US national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).JAMA Oncology,1(8),1051-1059.
9. ECOG-ACRIN Cancer Research Group (2019). ECOG performance status. Retrieved from https://ecog-acrin.org/resources/ecogperformance-status
10. Haley, A. C.,Calahan, C.,Gandhi, M.,West, D. P.,Rademaker, A.,Lacouture, M. E.(2011).Skin care management in cancer patients: An evaluation of quality of life and tolerability.Supportive Care in Cancer,19(4),545-554.
11. Jatoi, A.,Nguyen, P. L.(2008).Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy.Oncologist,13(11),1201-1204.
12. Joshi, S. S.,Ortiz, S.,Witherspoon, J. N.,Rademaker, A.,West, D. P.,Anderson, R.,Lacouture, M. E.(2010).Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.Cancer,116(16),3916-3923.
13. Lacouture, M. E.,Anadkat, M. J.,Bensadoun, R. J.,Bryce, J.,Chan, A.,Epstein, J. B.,Murphy, B. A.(2011).Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.Supportive Care in Cancer,19(8),1079-1095.
14. Lacouture, M. E.,Mitchell, E. P.,Piperdi, B.,Pillai, M. V.,Shearer, H.,Iannotti, N.,Yassine, M.(2010).Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.American Society of Clinical Oncology,28(8),1351-1357.
15. Lorusso, P.(2009).Toward evidence-based management of the dermatologic effects of EGFR inhibitors.Oncology,23(2),186-194.
16. Martin, N. V.,Pacifico, V.,Lai, S. E.,Rademaker, A.,Ortiz, S.,Aneja, M.,Lacouture, M.(2007).Management of rash to erlotinib and cetuximab: Results from the SERIES (skin and eye reactions to inhibitors of EGFR and kinaseS) clinic algorithm.Journal of Clinical Oncology,25,19556.
17. Melosky, B.,Burkes, R.,Rayson, D.,Alcindor, T.,Shear, N.,Lacouture, M.(2009).Management of skin rash during egfrtargeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations.Current Oncology,16(1),16-26.
18. Miles, M. B.,Huberman, A. M.(1994).Qualitative data analysis: An expanded sourcebook.Thousand Oaks, CA:Sage.
19. Mok, T. S.,Wu, Y. L.,Thongprasert, S.,Yang, C. H.,Chu, D. T.,Saijo, N.,Fukuoka, M.(2009).Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma.The New England Journal of Medicine,361,947-957.
20. National Cancer Institute (2010). Common terminology criteria for adverse events (CTCAE). Retrieved from https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
21. National Comprehensive Cancer Network (2018). NCCN clinical practice guideline in oncology: Non-small cell lung cancer. Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
22. Normando, S. R. C.,Cruz, F. M.,del Giglio, A.(2015).Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer.Anticancer Drugs,26(9),995-1003.
23. Osio, A.,Mateus, C.,Soria, J. C.,Massard, C.,Malka, D.,Boige, V.,Robert, C.(2009).Cutaneous side-effects in patients on longterm treatment with epidermal growth factor receptor inhibitors.British Journal of Dermatology,161(3),515-521.
24. Vigarios, E.,Epstein, J. B.,Sibaud, V.(2017).Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.Supportive Care in Cancer,25(5),1713-1739.
25. Wagner, L. I.,Lacouture, M. E.(2007).Dermatologic toxicities associated with EGFR inhibitors: The clinical psychologist's perspective: Impact on health-related quality of life and implications for clinical management of psychological sequelae.Oncology,21(11),34-36.
26. 江建平, C. P.,周繡玲, H. L.,,陳宇欽, Y. C.(2009)。標靶治療藥物相關皮膚併發症的臨床表徵與處置。腫瘤護理雜誌，9(2)，1-11。
27. 吳銘芳(2016)‧肺癌的標靶藥物治療 ‧取自http://web.csh.org.tw/web/222010/?p=604 [Wu, M. F. (2016). Targeted therapy of lung cancer. Retrieved from http://web.csh.org.tw/web/222010/?p=604]
28. 林如玉, J. Y.(2009)。台北市=Taipei，國立台灣大學護理學研究所=National Taiwan University。
29. 林芷亘, Z. X.(2017)。台南市=Tainan，長榮大學醫務管理學系=Chang Jung Christian University。
30. 陳冠宇(2018)‧肺癌的性別差異 ‧取自http://www.fma.org.tw/2008/E-6-2.html [Chen, C. Y. (2018). Gender difference on lung cancer. Retrieved from http://www.fma.org.tw/2008/E-6-2.html]
31. 陳秋慧, C. H.(2009)。上皮生長因子接受體抑制劑相關皮膚毒性之照護。腫瘤護理雜誌，9(2)，13-22。
32. 曾麗娟, L. C.(2016)。桃園市=Taoyuan，長庚大學護理學研究所=Chang Gung University。
33. 詹瑞君, J. C.,廖幼婕, Y. C.,李芸湘, Y. H.,賴裕和, Y. H.(2014)。接受標靶治療的肺癌病患身體心像改變之臨床照護。護理雜誌，61(4)，90-96。
34. 衛生福利部國民健康署(2018)‧105年癌症登記年報 ‧取自https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269&pid=10227 [Health Promotion Administration, Ministry of Health and Welfare (2018). Taiwan cancer registry introduction. Retrieved from https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269&pid=10227]
35. 癌症希望基金會 (2016) ‧標靶藥推陳出新肺腺癌活久活好 ‧取自 https://www.ecancer.org.tw/DynamicContent.aspx?unitID=10137&contentID=446 [HOPE Foundation for Cancer Care (2016). Target drug renewing live for a long time. Retrieved from https://www.ecancer.org.tw/DynamicContent.aspx?unitID=10137&contentID=446]